Dean Porter
Starting July 1, millions of Americans on Medicare will be able to get certain GLP-1 weight loss drugs for a flat $50 a month, thanks to a new demonstration program from the Centers for Medicare & Medicaid Services. The Medicare GLP-1 Bridge runs through December 31, 2027, and it marks the first time the program has opened this class of drugs to beneficiaries seeking treatment for obesity alone.
Medicare has historically drawn a hard line here. If you were prescribed a GLP-1 for type 2 diabetes or a related heart condition, coverage was possible. If your doctor prescribed the same drug purely for weight loss, you were on your own, often facing sticker prices that rival a car payment. The new pilot doesn't rewrite that rule permanently, but it does carve out a temporary lane specifically for weight management.
Who Actually Qualifies
Roughly 3.8 million Medicare beneficiaries could be eligible, according to estimates from the health policy research group KFF, based on 2023 data. Chris Klomp, who directs Medicare and serves as chief counselor at the Department of Health and Human Services, has put the number more conservatively at
Curtis Hernandez
Douglas Turner